Maximizing Efficacy and Minimizing Toxicity of ADCs Targeting HER2, HER3, and TROP-2: Strategies for Oncology Pharmacists

Get up to date on how oncology pharmacists can optimize care for patients receiving ADCs targeting HER2, HER3, and TROP-2 with downloadable slides, a frequently asked questions commentary, and an on-demand webcast capturing a live symposium at HOPA AC24. 

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC.

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Partners

Clinical Care Options, LLC

ProCE Banner